Kamaboko   Report issue

For profit Phase 1
Founded: Odawara Japan (1865)
Status: No NME R&D (1865)

Organization Overview

First Clinical Trial
2014
NCT02272543
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

fish surimi peptide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malnutrition (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1